Voriconazole
Product: Emixustat
Identifier : DBSNPE000244
Drug : DB00582 (Voriconazole)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Allele Name : CYPC19*17
Genotype(s) : (T;T) / (C;T)
Type(s) : Effect Directly Studied
Groups : Not Available
Description : Higher dose requirement
References :
- Moriyama B, Obeng AO, Barbarino J, Penzak SR, Henning SA, Scott SA, Agundez JA, Wingard JR, McLeod HL, Klein TE, Cross S, Caudle KE, Walsh TJ: Clinical Pharmacogenetics Implementation Consortium (CPIC(R)) Guideline for CYP2C19 and Voriconazole Therapy. Clin Pharmacol Ther. 2016 Dec 16. doi: 10.1002/cpt.583. [PubMed:27981572 ]
PMID: 24517977
Voriconazole
Product: Afatinib (dimaleate)
Identifier : DBSNPE005154
Drug : DB00582 (Voriconazole)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Allele Name : CYP2C19*2A
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, may lead to hepatotoxicity, visual disturbances, visual hallucinations, and other neurologic disorders
References :
- Moriyama B, Obeng AO, Barbarino J, Penzak SR, Henning SA, Scott SA, Agundez JA, Wingard JR, McLeod HL, Klein TE, Cross S, Caudle KE, Walsh TJ: Clinical Pharmacogenetics Implementation Consortium (CPIC(R)) Guideline for CYP2C19 and Voriconazole Therapy. Clin Pharmacol Ther. 2016 Dec 16. doi: 10.1002/cpt.583. [PubMed:27981572 ]
PMID: 18777108
Voriconazole
Product: DOXO-EMCH
Identifier : DBSNPE005155
Drug : DB00582 (Voriconazole)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Allele Name : CYP2C19*2B
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, may lead to hepatotoxicity, visual disturbances, visual hallucinations, and other neurologic disorders
References :
- Moriyama B, Obeng AO, Barbarino J, Penzak SR, Henning SA, Scott SA, Agundez JA, Wingard JR, McLeod HL, Klein TE, Cross S, Caudle KE, Walsh TJ: Clinical Pharmacogenetics Implementation Consortium (CPIC(R)) Guideline for CYP2C19 and Voriconazole Therapy. Clin Pharmacol Ther. 2016 Dec 16. doi: 10.1002/cpt.583. [PubMed:27981572 ]
PMID: 14679185
Voriconazole
Product: Palbociclib (hydrochloride)
Identifier : DBSNPE005156
Drug : DB00582 (Voriconazole)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Allele Name : CYP2C19*3
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, may lead to hepatotoxicity, visual disturbances, visual hallucinations, and other neurologic disorders
References :
- Moriyama B, Obeng AO, Barbarino J, Penzak SR, Henning SA, Scott SA, Agundez JA, Wingard JR, McLeod HL, Klein TE, Cross S, Caudle KE, Walsh TJ: Clinical Pharmacogenetics Implementation Consortium (CPIC(R)) Guideline for CYP2C19 and Voriconazole Therapy. Clin Pharmacol Ther. 2016 Dec 16. doi: 10.1002/cpt.583. [PubMed:27981572 ]
PMID: 9755289
Voriconazole
Product: CAL-130 (Hydrochloride)
Identifier : DBSNPE005157
Drug : DB00582 (Voriconazole)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Allele Name : CYP2C19*4
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, may lead to hepatotoxicity, visual disturbances, visual hallucinations, and other neurologic disorders
References :
- Moriyama B, Obeng AO, Barbarino J, Penzak SR, Henning SA, Scott SA, Agundez JA, Wingard JR, McLeod HL, Klein TE, Cross S, Caudle KE, Walsh TJ: Clinical Pharmacogenetics Implementation Consortium (CPIC(R)) Guideline for CYP2C19 and Voriconazole Therapy. Clin Pharmacol Ther. 2016 Dec 16. doi: 10.1002/cpt.583. [PubMed:27981572 ]
PMID: 8019769
Voriconazole
Product: Salinomycin
Identifier : DBSNPE005158
Drug : DB00582 (Voriconazole)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Allele Name : CYP2C19*5
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, may lead to hepatotoxicity, visual disturbances, visual hallucinations, and other neurologic disorders
References :
- Moriyama B, Obeng AO, Barbarino J, Penzak SR, Henning SA, Scott SA, Agundez JA, Wingard JR, McLeod HL, Klein TE, Cross S, Caudle KE, Walsh TJ: Clinical Pharmacogenetics Implementation Consortium (CPIC(R)) Guideline for CYP2C19 and Voriconazole Therapy. Clin Pharmacol Ther. 2016 Dec 16. doi: 10.1002/cpt.583. [PubMed:27981572 ]
PMID: 8019770
Voriconazole
Product: Pemetrexed (disodium)
Identifier : DBSNPE005159
Drug : DB00582 (Voriconazole)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Allele Name : CYP2C19*6
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, may lead to hepatotoxicity, visual disturbances, visual hallucinations, and other neurologic disorders
References :
- Moriyama B, Obeng AO, Barbarino J, Penzak SR, Henning SA, Scott SA, Agundez JA, Wingard JR, McLeod HL, Klein TE, Cross S, Caudle KE, Walsh TJ: Clinical Pharmacogenetics Implementation Consortium (CPIC(R)) Guideline for CYP2C19 and Voriconazole Therapy. Clin Pharmacol Ther. 2016 Dec 16. doi: 10.1002/cpt.583. [PubMed:27981572 ]
PMID: 1330591
Voriconazole
Product: Pemetrexed
Identifier : DBSNPE005160
Drug : DB00582 (Voriconazole)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Allele Name : CYP2C19*7
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, may lead to hepatotoxicity, visual disturbances, visual hallucinations, and other neurologic disorders
References :
- Moriyama B, Obeng AO, Barbarino J, Penzak SR, Henning SA, Scott SA, Agundez JA, Wingard JR, McLeod HL, Klein TE, Cross S, Caudle KE, Walsh TJ: Clinical Pharmacogenetics Implementation Consortium (CPIC(R)) Guideline for CYP2C19 and Voriconazole Therapy. Clin Pharmacol Ther. 2016 Dec 16. doi: 10.1002/cpt.583. [PubMed:27981572 ]
PMID: 27768754
Voriconazole
Product: Bicalutamide
Identifier : DBSNPE005161
Drug : DB00582 (Voriconazole)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Defining Change(s) :
- 557G>C (rs140278421 )
- 991A>G
Allele Name : CYP2C19*22
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, may lead to hepatotoxicity, visual disturbances, visual hallucinations, and other neurologic disorders
References :
- Moriyama B, Obeng AO, Barbarino J, Penzak SR, Henning SA, Scott SA, Agundez JA, Wingard JR, McLeod HL, Klein TE, Cross S, Caudle KE, Walsh TJ: Clinical Pharmacogenetics Implementation Consortium (CPIC(R)) Guideline for CYP2C19 and Voriconazole Therapy. Clin Pharmacol Ther. 2016 Dec 16. doi: 10.1002/cpt.583. [PubMed:27981572 ]
PMID: 25510459
Voriconazole
Product: BMX-IN-1
Identifier : DBSNPE005162
Drug : DB00582 (Voriconazole)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Defining Change(s) :
- 99C>T (rs17885098 )
- 991A>G (rs3758581 )
- 1004G>A (rs118203757 )
- 1197A>G
Allele Name : CYP2C19*24
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, may lead to hepatotoxicity, visual disturbances, visual hallucinations, and other neurologic disorders
References :
- Moriyama B, Obeng AO, Barbarino J, Penzak SR, Henning SA, Scott SA, Agundez JA, Wingard JR, McLeod HL, Klein TE, Cross S, Caudle KE, Walsh TJ: Clinical Pharmacogenetics Implementation Consortium (CPIC(R)) Guideline for CYP2C19 and Voriconazole Therapy. Clin Pharmacol Ther. 2016 Dec 16. doi: 10.1002/cpt.583. [PubMed:27981572 ]
PMID: 21357533
Voriconazole
Product: Metiamide
Identifier : DBSNPE005163
Drug : DB00582 (Voriconazole)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Allele Name : CYP2C19*35
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, may lead to hepatotoxicity, visual disturbances, visual hallucinations, and other neurologic disorders
References :
- Moriyama B, Obeng AO, Barbarino J, Penzak SR, Henning SA, Scott SA, Agundez JA, Wingard JR, McLeod HL, Klein TE, Cross S, Caudle KE, Walsh TJ: Clinical Pharmacogenetics Implementation Consortium (CPIC(R)) Guideline for CYP2C19 and Voriconazole Therapy. Clin Pharmacol Ther. 2016 Dec 16. doi: 10.1002/cpt.583. [PubMed:27981572 ]
PMID: 11156581